Back to results
US 9,308,278 B2Granted
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
AssigneeAgensys, Inc.
InventorsMichael Torgov, Robert Kendall Morrison, Aya Jakobovits, Jean Gudas, Zili An
Life of this patent
Estimating the term…
Abstract
Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
Claims14
An antibody drug conjugate obtained by a process comprising the step of:
- conjugating an antibody or antigen binding fragment thereof to monomethyl auristatin F (MMAF), which antibody or antigen binding fragment thereof is expressed by a host cell comprising a nucleic acid sequence encoding an amino acid sequence of a VH region consisting of SEQ ID NO:7, from residues 20 to 142, and a nucleic acid sequence encoding an amino acid sequence of a VL region consisting of SEQ ID NO:8, from residues 20 to 127, thereby producing the antibody drug conjugate.
An antibody drug conjugate obtained by a process comprising:
- (a) culturing a host cell comprising a nucleic acid sequence encoding an amino acid sequence of an antibody or antigen binding fragment thereof comprising a VH and a VL region into a host cell, wherein the VH region consists of SEQ ID NO:7, from residues 20 to 142, and the VL region consists of SEQ ID NO:8, from residues 20 to 127, such that the antibody or antigen binding fragment thereof is expressed,
- (b) conjugating the antibody or fragment thereof expressed in step (a) to monomethyl auristatin F (MMAF), and
- (c) isolating the antibody or fragment conjugated to MMAF in step (b), thereby producing the antibody drug conjugate.
An antibody drug conjugate obtained by a process comprising:
- (a) transfecting a nucleic acid sequence encoding an amino acid sequence of an antibody or an antigen binding fragment thereof comprising a VH region and a VL region into a host cell, wherein the VH region consists of SEQ ID NO:7, from residues 20 to 142, and the VL region consists of SEQ ID NO:8, from residues 20 to 127,
- (b) culturing the host cell and expressing the antibody or antigen binding fragment thereof,
- (c) conjugating the antibody or antigen binding fragment thereof expressed in step (b) to monomethyl auristatin F (MMAF), and
- (d) isolating the antibody or fragment conjugated to MMAF in step (c), thereby producing the antibody drug conjugate.
1 more element
Dependencies are inferred from the claim text.